-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES ICECURE'S POST-MARKETING "CHOICE" STUDY FOR PROSENSE® CRYOABLATION IN THE LOCAL TREATMENT OF LOW-RISK BREAST CANCER

Reuters·03/11/2026 12:30:06

Please log in to view news